A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

  • End date
    Apr 30, 2025
  • participants needed
  • sponsor
    Astellas Pharma Global Development, Inc.
Updated on 15 September 2022
tumor markers
measurable disease
international normalized ratio
neutrophil count
pancreatic adenocarcinoma
liver metastasis
tumor cells
blood transfusion
adjuvant therapy
cancer chemotherapy
metastatic pancreatic cancer
metastatic pancreatic adenocarcinoma


The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment.

This study will also evaluate tumor markers and pharmacokinetics (PK) of zolbetuximab, Nab-P and GEM, and health-related quality of life (HRQoL).


This study will have a safety lead in phase and a randomization phase.

Condition Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Treatment Gemcitabine, Nab-paclitaxel, Zolbetuximab
Clinical Study IdentifierNCT03816163
SponsorAstellas Pharma Global Development, Inc.
Last Modified on15 September 2022


Yes No Not Sure

Inclusion Criteria

A female subject is eligible to participate if she is not pregnant or lactating and at least 1 of the following conditions applies
Not a woman of childbearing potential (WOCBP) OR
WOCBP who agrees to follow the contraceptive guidance throughout the treatment period and for at least 6 months after the final study drug administration
Female subject must agree not to breastfeed starting at screening and throughout the
study period, and for 6 months after the final study drug administration
Female subject must not donate ova starting at screening and throughout the study period, and for 6 months after the final study drug administration
A male subject with female partner(s) of child-bearing potential must agree to use contraception during the treatment period and for at least 6 months after the final study drug administration
A male subject must not donate sperm during the treatment period and for at least 6 months after the final study drug administration
Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the study period and for 6 months after the final study drug administration
Subject agrees not to participate in other interventional studies while receiving study drug in present study
Subject has histologically or cytologically confirmed adenocarcinoma of pancreas
Subjects must have metastatic pancreatic adenocarcinoma that has not been previously treated with chemotherapy
Prior treatment with fluorouracil (5-FU) or GEM administered as a radiation sensitizer during and up to 4 weeks after radiation therapy is allowed
If a subject received adjuvant therapy, tumor recurrence or disease progression must have occurred at least 6 months after completing the last dose of the adjuvant therapy
Subjects whose disease progressed on prior treatment with Nab-P and GEM are not eligible
Subject has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Subject has a measurable lesion(s) on at least 1 metastatic site based on RECIST 1.1
within 28 days prior to randomization. For subjects with only 1 measurable
Subject must meet all of the following criteria based on the laboratory tests that will be collected within 14 days prior to randomization. In case of multiple laboratory data within this period, the most recent data should be used
lesion and prior radiotherapy, the lesion must be outside the field of prior
radiotherapy or must have documented progression following radiation therapy
Subject's tumor sample has CLDN18.2 expression in ≥ 75% of tumor cells demonstrating moderate to strong membranous staining as determined by central immunohistochemistry (IHC) testing
Subject has predicted life expectancy ≥ 12 weeks
Hemoglobin ≥ 9 g/dl (no transfusion within 14 days of start of study treatment)
Absolute neutrophil count ≥ 1.5 x 10^9/L
Platelets ≥ 100 x 10^9/L
Albumin ≥ 2.5 g/dL
Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN without liver metastases (≤ 5 x ULN if liver metastases are present)
Estimated creatinine clearance ≥ 30 mL/min
Prothrombin time/international normalized ratio (INR) and partial thromboplastin time ≤ 1.5 x ULN (except for subjects receiving anticoagulation therapy)

Exclusion Criteria

Subject has received other investigational treatment within 28 days prior to randomization
Subject has received systemic immunosuppressive therapy, including systemic corticosteroids within 14 days prior to randomization. Subject using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 30 mg per day of hydrocortisone or up to 10 mg per day of prednisone), receiving a single dose of systemic corticosteroids or receiving systemic corticosteroids as premedication for radiologic imaging contrast use are allowed
Subject has prior severe allergic reaction or intolerance to known ingredients of zolbetuximab or other monoclonal antibody, including humanized or chimeric antibodies
Subject has known immediate or delayed hypersensitivity, intolerance or contraindication to any component of study treatment
Subject has a known history of a positive test for human immunodeficiency virus infection or known active hepatitis B (positive HBs antigen [Ag]) or hepatitis C infection. NOTE: Screening for these infections should be conducted per local requirements
Subject has a history of interstitial pneumonia or pulmonary fibrosis
For subjects who are negative for HBs Ag, but hepatitis B core antibody positive, a hepatitis B virus DNA test will be performed and if positive, the subject will be excluded
Subject has received radiotherapy for metastatic pancreatic adenocarcinoma ≤ 14 days prior to randomization and has not recovered from any related toxicity
Subjects with positive hepatitis C serology but negative hepatitis C virus RNA test results are eligible
Subjects treated for hepatitis C with undetectable viral load results are eligible
Subject has significant cardiovascular disease, including
Subject has an active autoimmune disease that has required systemic treatment in the past 3 months prior to randomization
Subject has active infection requiring systemic therapy that has not completely resolved per investigator judgment within 7 days prior to randomization
History of clinically significant ventricular arrhythmias (i.e., sustained ventricular tachycardia, ventricular fibrillation or Torsades de Pointes)
QTc interval > 450 msec for male subjects; QTc interval > 470 msec for female subjects
Congestive heart failure (defined as New York Heart Association Class III or IV), myocardial infarction, unstable angina, coronary angioplasty, coronary stenting, coronary artery bypass graft, cerebrovascular accident or hypertensive crisis within 6 months prior to randomization
Subject has pleural effusion or ascites ≥ Grade 3
Cardiac arrhythmias requiring anti-arrhythmic medications (Subjects with rate controlled atrial fibrillation for > 1 month prior to randomization.)
Psychiatric illness or social situations that would preclude study compliance
Subject has another malignancy for which treatment is required
Subject has any concurrent disease, infection or co-morbid condition that interferes with the ability of the subject to participate in the study, which places the subject at undue risk or complicates the interpretation of data
Subject has a history of central nervous system metastases and/or carcinomatous
meningitis from pancreatic adenocarcinoma
Subject has known peripheral sensory neuropathy ≥ Grade 2 unless the absence of deep tendon reflexes is the sole neurological abnormality
Subject has had a major surgical procedure ≤ 28 days prior to randomization
Subject without complete recovery from a major surgical procedure ≤ 14 days prior to randomization
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note